Innovative Oncolytic Virotherapy Unlocking New Possibilities in Cancer Treatment

DIFF-OV 001 is an investigational oncolytic virus therapy based on a recombinant Vesicular Stomatitis Virus (VSV) vector. Designed to safely and efficiently target tumor cells, it not only destroys cancer cells but also stimulates a potent antitumor immune response. DIFF-OV 001 represents a promising candidate in oncolytic virotherapy, with the potential to address multiple cancer indications.

Figure 1. Structure and Genome of Vesicular Stomatitis Virus (VSV)​

Why DIFF-OV 001 Stands Out

• Safe Systemic Administration: Eliminates the neurotoxicity of wild-type VSV, allowing broader and safer clinical use.
• Powerful Tumor Killing:Rapid replication and strong lytic activity lead to fast, effective tumor destruction.
• Immune System Activation:Stimulates a robust antitumor immune response, achieving complete tumor regression and long-term tumor-free survival in preclinical models.
• Scalable Platform:Cost-effective, high-yield production, adaptable to multiple cancer types for broad therapeutic development.

 

Strong Market Potential

The global oncolytic virus therapy market is projected to grow from USD 87.1 million in 2024 to USD 7,549 million by 2030 (Frost & Sullivan). Despite this rapid growth, only a limited number of oncolytic virus therapies are approved worldwide, highlighting a blue-ocean opportunity for innovative candidates like DIFF-OV 001.

Colorectal cancer is the third most common cancer and the second leading cause of cancer-related deaths worldwide. In 2024, there were about 2.1 million new cases, and the number is expected to keep rising due to lifestyle and dietary changes.

The global market for colorectal cancer therapies reached USD 25.4 billion in 2024, highlighting a significant opportunity for innovative treatments.

Preclinical Highlights

• Complete tumor regression in over 60% of mice in a CT26 colon cancer model.
• Tumor growth suppression in 100% of mice in HT-29 human colon adenocarcinoma model.
• Enhanced safety profile with no significant weight loss or reduced survival in preclinical studies.

 

Partner with Us

DIFF Biotech is seeking global collaborations to accelerate development, registration, and commercialization of DIFF-OV 001.

Contact: bd@diff-biotech.com